BALTIMORE, March 5 /PRNewswire/ -- Alba Therapeutics Corporation today announced the appointment of Linda M. Arterburn, Ph.D. as its Senior Director, In Vivo Pharmacology & Toxicology. Dr. Arterburn will be responsible for leading Alba’s in vivo pharmacology and toxicology efforts supporting the Company’s zonulin antagonist and agonist programs.
“We are very pleased that Dr. Arterburn is joining Alba,” said Blake Paterson, M.D., Chief Executive Officer of Alba Therapeutics. “Linda is an accomplished scientific executive and brings a broad range of biotechnology research and development management experience to Alba.” Prior to joining Alba, Dr. Arterburn was Executive Director of Discovery Research at Martek Biosciences. In this capacity, she initiated and led an inflammation research program and was lead inventor of several patents involving novel anti- inflammatory molecules. She previously led Clinical Research and Scientific Affairs at Martek where she played a key role in the regulatory authorizations for the addition of Martek’s fatty acid products, DHA and ARA, to infant formula in the United States and Canada. Dr. Arterburn also spent seven years at W.R. Grace & Co., where she led in vitro toxicology research programs, and then served as Manager of Technology and Planning for the research portfolio of this Fortune 100 company.
Dr. Arterburn holds a PhD in Pharmacology and the Molecular Sciences from the Johns Hopkins University School of Medicine, and a Bachelor’s Degree in Biochemistry from the University of Wisconsin.
About Alba
Alba Therapeutics Corporation is a privately held biopharmaceutical company based in Baltimore, Maryland. Alba is dedicated to commercializing disease-modifying therapeutics and vaccine and drug delivery adjuvants based on the zonulin pathway. Alba’s lead molecule, AT-1001, is targeted towards the treatment of Celiac Disease and other autoimmune diseases including IBD and Type 1 Diabetes. AT-1001 is currently under investigation in a multicenter, double blind, placebo controlled Phase II dose ranging study to evaluate the safety, tolerability and efficacy of AT-1001 in 86 Celiac Disease subjects during gluten challenge.
Contact: Stuart Sedlack, SVP, Corporate Development Phone: 410-319-0780 E-mail: info@albatherapeutics.com Web site: http://www.albatherapeutics.com
Alba Therapeutics Corporation
CONTACT: Stuart Sedlack of Alba Therapeutics Corporation, SVP, CorporateDevelopment, +1-410-319-0780, or info@albatherapeutics.com
Web site: http://www.albatherapeutics.com/
